Wuxi Biologics (Cayman) Inc.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. carries a market capitalization of 14.55B, placing it among publicly traded companies globally. Its enterprise value stands at 13.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Wuxi Biologics (Cayman) Inc.'s next confirmed earnings release is scheduled for March 23, 2027.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. has 4.13B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Wuxi Biologics (Cayman) Inc.'s stock has gained approximately 27.91% over the past 52 weeks. The 50-day moving average sits at 5.63, while the 200-day moving average is 4.37.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. holds 1.91B in cash and equivalents against 377.81M in total debt, resulting in a net debt position of -994.51M. Total book value stands at 5.75B, with working capital of 2.41B providing operational flexibility.

Wuxi Biologics (Cayman) Inc.'s most recent stock split took place on November 16, 2020 with a 1:3 split ratio.